Biotech Values

[DewDiligence]

VRTX adds ribavirin arm to VX-222/Telaprevir all-oral HCV trial:

http://finance.yahoo.com/news/Vertex-Announces-Plans-to-bw-130493646.html?x=0&.v=1

The trial with the new ribavirin arm is the one where VRTX recently dropped the lowest dose of VX-222 due to viral breakthrough (#msg-55917569).

VRTX’s decision to add ribavirin is in sync with BI, who is already using ribavirin in its combination study of BI 201335 and BI 207127 (#msg-56271789).